the impact of fungal pathogens on human health is currently spiraling out of control, with the global mortality rate for fungal diseases now exceeding that of malaria (Brown et al., 2012). Fungal pathogens cause invasive diseases and chronic infections, in both immunocompromised and immunocompetent individuals. Despite this public health burden, fungal infections have been widely neglected in terms of research funding compared to other infectious diseases (Fisher et al., 2018).
I am currently a Research Fellow on the Wellcome Trust grant "Understanding and mitigating the impact of emerging antifungal resistance". This role involves population genomics genetic and biostatistical analyses of Aspergillus fumigatus, an environmental fungus to which all humans are exposed causing disease in millions, and which is rapidly evolving resistance to azole antifungal drugs worldwide. My research aims to understand the risk that azole-resistant aspergillosis presents to public health by identifying the extent to which patients are acquiring resistant infections from environmental sources.
Alongside this research, I continue to work on the emerging human pathogen Candida auris; this pathogen displays unique characteristics that have led it to be a global public health concern, namely, its ability to cause nosocomial outbreaks, lack of vulnerability to hygiene and infection control measures, and intrinsic drug resistance.
I am also continuing my research on the fungal pathogen Cryptococcus neoformans, which predominantly infects immunocompromised individuals, and is responsible for almost a quarter of AIDS-related deaths in Africa.
et al., 2020, The one health problem of azole resistance in Aspergillus fumigatus: current insights and future research agenda, Fungal Biology Reviews, Vol:34, ISSN:1749-4613, Pages:202-214
et al., 2020, Cross-Disciplinary Genomics Approaches to Studying Emerging Fungal Infections, Life, Vol:10, ISSN:2075-1729
et al., 2020, Rapid detection of azole-resistant Aspergillus fumigatus in clinical and environmental isolates using lab-on-a-chip diagnostic system, Journal of Clinical Microbiology, Vol:58, ISSN:0095-1137, Pages:1-11
et al., 2020, Confronting and mitigating the risk of COVID-19 Associated Pulmonary Aspergillosis (CAPA), European Respiratory Journal, Vol:56, ISSN:0903-1936, Pages:1-10